iCAD, Inc. (ICAD)
| Market Cap | 432.71M |
| Revenue (ttm) | 31.79M |
| Net Income (ttm) | -7.44M |
| Shares Out | 24.98M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $17.32 |
| Previous Close | $16.99 |
| Change ($) | 0.33 |
| Change (%) | 1.94% |
| Day's Open | 16.89 |
| Day's Range | 16.89 - 17.65 |
| Day's Volume | 62,781 |
| 52-Week Range | 8.32 - 21.44 |
Icad (ICAD) delivered earnings and revenue surprises of 36.36% and 6.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
First Quarter Revenues of $8.6 Million Represented 32% Year-Over-Year Growth Driven by 28% Growth in Detection Revenue and 41% Growth in Therapy Revenue
NASHUA, N.H., April 20, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will r...
Company expects preliminary estimated revenues to exceed $8.1 million
The FDA has approved iCAD Inc's (NASDAQ: ICAD) ProFound AI Version 3.0 for Digital Breast Tomosynthesis (also known as “3D” mammography used to improve the ability to detect early breast cancers). Compa...
Company's third generation AI solution offers significant improvement in algorithm specificity performance and faster processing compared to previous versions of the software
Company showcased expanded ProFound AI platform, including ProFound AI Risk, the world's first clinical decision support tool that provides a highly accurate short-term risk estimation specific to each ...
Icad (ICAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NASHUA, N.H., March 03, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael K...
NASHUA, N.H., March 03, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced...
NASHUA, N.H., March 02, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced...
iCAD (ICAD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Icad (ICAD) delivered earnings and revenue surprises of 25.00% and 30.64%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI® Product Revenue
NASHUA, N.H., Feb. 18, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will re...
Icad (ICAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHUA, N.H., Feb. 16, 2021 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael ...
As of late, it has definitely been a great time to be an investor in iCAD, Inc. (ICAD).
NASHUA, N.H., Jan. 19, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Kl...
New ProFound AI risk software, offering a 2-year projected risk score to be featured New ProFound AI risk software, offering a 2-year projected risk score to be featured
International Multi-Center Study to Commence January 2021
Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services' Network Agreement Positions Both ...
Groundbreaking ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm to Risk-Adapted Precision Screening, Individualized for Each Woman Groundbreaking ProFound AI Risk Help...
Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types
Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji
iCAD, Inc. (ICAD) CEO Michael Klein on Q3 2020 Results - Earnings Call Transcript
Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively
NASHUA, N.H., Oct. 29, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will ...
iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Soluti...
Contract with market-leading enterprise imaging provider expands access to ProFound AI for hospitals and imaging centers across North America Contract with market-leading enterprise imaging provider exp...
New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery New, Encouraging Results and Overall Patient Survival Numbers to be Presented at Europe...
Webinar Taking Place on Wednesday, October 21st @ 10amET Webinar Taking Place on Wednesday, October 21st @ 10amET
IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therap...
NASHUA, N.H., Sept. 18, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today provided commentary...
Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settings Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settings
NASHUA, N.H., Aug. 27, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that manage...
NASHUA, N.H., Aug. 10, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Micha...
iCAD, Inc. (ICAD) CEO Michael Klein on Q2 2020 Results - Earnings Call Transcript
Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe
NASHUA, N.H., July 28, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it wil...
First and only commercially available clinical decision support tool provides accurate two-year breast cancer risk estimation personalized for each woman
Leading-edge artificial intelligence (AI) software allows patients to receive “real time” essential breast screening amidst pandemic Leading-edge artificial intelligence (AI) software allows patients to...
NASHUA, N.H., June 29, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the c...
NASHUA, N.H., April 23, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (Nasdaq: ICAD) today announced it has entered into definitive agreements with several institutional investors for the purchase and ...
Educational awareness forum to feature leading experts in discussions on risk adaptive tools and pragmatic solutions to enhance patient care during COVID-19 pandemic
NASHUA, N.H., March 31, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it h...
iCAD, Inc. (ICAD) CEO Michael Klein on Q4 2019 Results - Earnings Call Transcript
iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solutio...
World’s first and largest open AI Marketplace expands access to ProFound AI for U.S. radiologists, 80 percent of whom use Nuance’s radiology reporting system World’s first and largest open AI Marketplac...
Company Unveils New Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging Intelligence Technology to Correlate Findings Over Time Company Unveils New Initiative, ProFound AI Powe...
About ICAD
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calci... [Read more...]
| Industry Health Information Services | IPO Date Dec 3, 1986 |
| Stock Exchange NASDAQ | Ticker Symbol ICAD |
Financial Performance
In 2020, iCAD, Inc.'s revenue was $29.70 million, a decrease of -5.24% compared to the previous year's $31.34 million. Losses were -$17.61 million, 30.0% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for iCAD, Inc. stock is "Buy." The 12-month stock price forecast is 24.40, which is an increase of 40.88% from the latest price.